KEGG   DISEASE: ホジキンリンパ腫
エントリ  
H00007                                                             

名称    
ホジキンリンパ腫
概要    
Hodgkin's lymphoma (HL) is one of the most frequent lymphomas in the Western world and often affects young adults. HL is subdivided into classical and nodular lymphocyte-predominant forms. About 95% of cases are classical HL, and 5% are nodular lymphocyte-predominant HL (NLPHL). A characteristic feature of HL is the rareness of the tumor cells, which are called Hodgkin's and Reed/Sternberg (HRS) cells in classical HL and lymphocytic and histiocytic (L&H) cells in NLPHL. These cells represent only about 1% of the cellular infiltrate, while the vast majority of infiltrating cells are T lymphocytes, histiocytes, eosinophilic granulocytes and plasma cells. HRS cells show constitutive activity of both the classical and alternative NF-{kappa}B signalling pathways, which is probably a major pathogenetic mechanism in Hodgkin's lymphoma. The NF-{kappa}B activity in HRS cells is probably mediated by diverse mechanisms: receptor signalling through CD40, RANK, BCMA, and TACI, genomic REL amplification, destructive mutations in IKBA and IKBE. In HL pathogenesis associated with Epstein-Barr virus infection, the activation of NF-{kappa}B is induced by viral latent membrane protein 1 (LMP1).
カテゴリ  
がん
階層分類  
ヒト疾患 [BR:jp08402]
 がん
  造血組織およびリンパ系組織のがん
   H00007  ホジキンリンパ腫
ICD-11 による疾患分類 [BR:jp08403]
 02 Neoplasms
  Neoplasms of haematopoietic or lymphoid tissues
   2B30  Hodgkin lymphoma
    H00007  ホジキンリンパ腫
関連パスウェイ
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
hsa05169  Epstein-Barr virus infection
hsa05203  Viral carcinogenesis
ネットワーク
  エレメント
N00123  Amplified REL to transcription
N00223  EBV EBNA1 to p53-mediated transcription
N00224  EBV EBNALP RBP-Jk-mediated transcription
N00225  EBV EBNA2 to RBP-Jk-mediated transcription
N00226  EBV EBNA3A/3B/3C to RBP-Jk-mediated transcription
N00262  EBV EBNA3C to intrinsic apoptotic pathway
N00263  EBV EBNA3C to p53-mediated transcription
N00264  EBV EBNA3C to p27-Cell cycle G1/S
N00265  EBV LMP1 to NFKB signaling pathway
N00266  EBV LMP2A to PI3K signaling pathway
N00466  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00467  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00468  EBV BPLF1 to TLR2/4-NFKB signaling pathway
N00470  EBV BGLF4 to RIG-I-like receptor signaling pathway
N00471  EBV LMP2A/2B to IFN signaling pathway
N00472  EBV LMP1 to IFN signaling pathway
N00473  EBV BGLF4 to IFN signaling pathway
N00474  EBV BHRF1 to intrinsic apoptotic pathway
N00475  EBV BHRF1 to intrinsic apoptotic pathway
N00476  EBV BHRF1 to intrinsic apoptotic pathway
N00477  EBV BHRF1 to crosstalk between extrinsic and intrinsic apoptotic pathways
N00478  EBV BARF1 to intrinsic apoptotic pathway
N00479  EBV BNLF2a to antigen processing and presentation by MHC class I molecules
N00480  EBV BILF1 to antigen processing and presentation by MHC class I molecules
N00481  EBV BZLF1 to p53-mediated transcription
N00482  EBV EBNA3C to p27-Cell cycle G1/S
N00483  EBV EBNA3C to cell cycle G1/S
N00484  EBV EBNA3C to cell cycle G1/S
N00485  EBV LMP1 to PI3K signaling pathway
N00486  EBV LMP1 to Jak-STAT signaling pathway
N00488  EBV LMP2A to BCR signaling pathway
N01265  EBV vIL10 to IL10R signaling
N01281  EBV BARF1 to CSF1R sigaling
病因遺伝子 
IKBA (mutation) [HSA:4792] [KO:K04734]
IKBE (mutation) [HSA:4794] [KO:K05872]
c-rel (amplification) [HSA:5966] [KO:K09254]
CD95 (mutation) [HSA:355] [KO:K04390]
病原体   
Human herpesvirus 4 (Epstein-Barr virus) [GN:T40079]
治療薬   
デキサメタゾン [DR:D00292]
デキサメタゾンリン酸エステルナトリウム [DR:D00975]
ベタメタゾンリン酸エステルナトリウム [DR:D00972]
トリアムシノロンアセトニド [DR:D00983]
ヒドロコルチゾン [DR:D00088]
ヒドロコルチゾンコハク酸エステルナトリウム [DR:D00978]
コルチゾン酢酸エステル [DR:D00973]
トリアムシノロン [DR:D00385]
ベタメタゾン [DR:D00244]
プレドニゾロン [DR:D00472]
プレドニゾロンコハク酸エステルナトリウム [DR:D01239]
メチルプレドニゾロン [DR:D00407]
メチルプレドニゾロンコハク酸エステルナトリウム [DR:D00751]
メチルプレドニゾロン酢酸エステル [DR:D00979]
イホスファミド [DR:D00343]
メルファラン [DR:D00369]
ニムスチン塩酸塩 [DR:D01059]
ラニムスチン [DR:D01760]
ダカルバジン [DR:D00288]
シタラビン [DR:D00168]
ゲムシタビン塩酸塩 [DR:D01155]
ブレオマイシン塩酸塩 [DR:D03229]
ペプロマイシン硫酸塩 [DR:D02063]
ドキソルビシン塩酸塩 [DR:D01275]
エピルビシン塩酸塩 [DR:D02214]
アクラルビシン塩酸塩 [DR:D01911]
ピラルビシン塩酸塩 [DR:D08386]
ビンブラスチン硫酸塩 [DR:D01068]
ビンクリスチン硫酸塩 [DR:D02197]
ビンデシン硫酸塩 [DR:D01769]
エトポシド [DR:D00125]
ミトキサントロン塩酸塩 [DR:D02166]
シスプラチン [DR:D00275]
カルボプラチン [DR:D01363]
プロカルバジン塩酸塩 [DR:D00478]
ブレンツキシマブベドチン [DR:D09587] (CD30陽性)
ニボルマブ [DR:D10316]
ペムブロリズマブ [DR:D10574]
L-アスパラギナーゼ [DR:D02997]
ソブゾキサン [DR:D01404]
コメント  
ICD-O: 9650/3, Tumor type: Classical Hodgkin lymphoma
ICD-O: 9663/3, Tumor type: Nodular sclerosis classical Hodgkin lymphoma
ICD-O: 9651/3, Tumor type: Lymphocyte-rich classical Hodgkin lymphoma
ICD-O: 9652/3, Tumor type: Mixed cellularity classical Hodgkin lymphoma
ICD-O: 9653/3, Tumor type: Lymphocyte-depleted classical Hodgkin lymphoma
リンク   
ICD-11: 2B30
ICD-10: C81
MeSH: D006689
文献    
PMID:15618006 (tumor type)
  著者
Kuppers R, Hansmann ML.
  タイトル
The Hodgkin and Reed/Sternberg cell.
  雑誌
Int J Biochem Cell Biol 37:511-7 (2005)
DOI:10.1016/j.biocel.2003.10.025
文献    
PMID:15803153 (gene, carcinogen, tumor type)
  著者
Kuppers R.
  タイトル
Mechanisms of B-cell lymphoma pathogenesis.
  雑誌
Nat Rev Cancer 5:251-62 (2005)
DOI:10.1038/nrc1589
文献    
PMID:16385563 (gene, carcinogen)
  著者
Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R.
  タイトル
Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.
  雑誌
Int J Cancer 118:1853-61 (2006)
DOI:10.1002/ijc.21716
文献    
PMID:15760280 (carcinogen)
  著者
Schottenfeld D, Beebe-Dimmer JL.
  タイトル
Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions.
  雑誌
Annu Rev Public Health 26:37-60 (2005)
DOI:10.1146/annurev.publhealth.26.021304.144402
文献    
PMID:12078906 (marker)
  著者
Zander T, Wiedenmann S, Wolf J.
  タイトル
Prognostic factors in Hodgkin's lymphoma.
  雑誌
Ann Oncol 13 Suppl 1:67-74 (2002)
DOI:10.1093/annonc/mdf613
文献    
PMID:11142480 (marker)
  著者
Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M.
  タイトル
Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
  雑誌
Ann Oncol 11:1405-11 (2000)
DOI:10.1023/A:1026551727795

» English version

DBGET integrated database retrieval system